Safety profile of autologous macrophage therapy for liver cirrhosis.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
12
05
2019
accepted:
29
08
2019
pubmed:
9
10
2019
medline:
22
1
2020
entrez:
9
10
2019
Statut:
ppublish
Résumé
Therapies to reduce liver fibrosis and stimulate organ regeneration are urgently needed. We conducted a first-in-human, phase 1 dose-escalation trial of autologous macrophage therapy in nine adults with cirrhosis and a Model for End-Stage Liver Disease (MELD) score of 10-16 (ISRCTN 10368050). Groups of three participants received a single peripheral infusion of 10
Identifiants
pubmed: 31591593
doi: 10.1038/s41591-019-0599-8
pii: 10.1038/s41591-019-0599-8
doi:
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1560-1565Subventions
Organisme : Medical Research Council
ID : MC_PC_16043
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K017047/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M007588/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G84/6205
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R015635/1
Pays : United Kingdom
Références
Asrani, S. K., Devarbhavi, H., Eaton, J. & Kamath, P. S. Burden of liver diseases in the world. J. Hepatol. 70, 151–171 (2019).
doi: 10.1016/j.jhep.2018.09.014
D’Amico, G., Garcia-Tsao, G. & Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 44, 217–231 (2006).
doi: 10.1016/j.jhep.2005.10.013
Forbes, S. J., Gupta, S. & Dhawan, A. Cell therapy for liver disease: from liver transplantation to cell factory. J. Hepatol. 62, S157–S169 (2015).
doi: 10.1016/j.jhep.2015.02.040
Schuppan, D. & Kim, Y. O. Evolving therapies for liver fibrosis. J. Clin. Invest. 123, 1887–1901 (2013).
doi: 10.1172/JCI66028
Duffield, J. S. et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 115, 56–65 (2005).
doi: 10.1172/JCI200522675
Gouw, A. S., Clouston, A. D. & Theise, N. D. Ductular reactions in human liver: diversity at the interface. Hepatology 54, 1853–1863 (2011).
doi: 10.1002/hep.24613
Boulter, L. et al. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat. Med 18, 572–579 (2012).
doi: 10.1038/nm.2667
Ramachandran, P. et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc. Natl Acad. Sci. USA 109, E3186–E3195 (2012).
doi: 10.1073/pnas.1119964109
Fallowfield, J. A. et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J. Immunol. 178, 5288–5295 (2007).
doi: 10.4049/jimmunol.178.8.5288
Bird, T. G. et al. Bone marrow injection stimulates hepatic ductular reactions in the absence of injury via macrophage-mediated TWEAK signaling. Proc. Natl Acad. Sci. USA 110, 6542–6547 (2013).
doi: 10.1073/pnas.1302168110
Fraser, A. R. et al. Development, functional characterization and validation of methodology for GMP-compliant manufacture of phagocytic macrophages: a novel cellular therapeutic for liver cirrhosis. Cytotherapy 19, 1113–1124 (2017).
doi: 10.1016/j.jcyt.2017.05.009
Moore, J. K. et al. Phenotypic and functional characterization of macrophages with therapeutic potential generated from human cirrhotic monocytes in a cohort study. Cytotherapy 17, 1604–1616 (2015).
doi: 10.1016/j.jcyt.2015.07.016
Foucher, J. et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55, 403–408 (2006).
doi: 10.1136/gut.2005.069153
Hutchinson, J. A. et al. Cutting Edge: immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J. Immunol. 187, 2072–2078 (2011).
doi: 10.4049/jimmunol.1100762
Sharkey, J. et al. Functionalized superparamagnetic iron oxide nanoparticles provide highly efficient iron-labeling in macrophages for magnetic resonance-based detection in vivo. Cytotherapy 19, 555–569 (2017).
doi: 10.1016/j.jcyt.2017.01.003
Thomas, J. A. et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration and function. Hepatology 53, 2003–2015 (2011).
doi: 10.1002/hep.24315
Newsome, P. N. et al. Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 3, 25–36 (2018).
doi: 10.1016/S2468-1253(17)30326-6
Younossi, Z. M. et al. Impact of liver transplantation on health-related quality of life. Liver Transpl. 6, 779–783 (2000).
doi: 10.1053/jlts.2000.18499
Younossi, Z. M., Guyatt, G., Kiwi, M., Boparai, N. & King, D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 45, 295–300 (1999).
doi: 10.1136/gut.45.2.295
Le Tourneau, C., Lee, J. J. & Siu, L. L. Dose escalation methods in phase I cancer clinical trials. J. Natl Cancer Inst. 101, 708–720 (2009).
doi: 10.1093/jnci/djp079
Kullak-Ublick, G. A. et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 66, 1154–1164 (2017).
doi: 10.1136/gutjnl-2016-313369
Mehta, R. L. et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 11, R31 (2007).
doi: 10.1186/cc5713
Henter, J. I. et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48, 124–131 (2007).
doi: 10.1002/pbc.21039
Tinegate, H. et al. Guideline on the investigation and management of acute transfusion reactions. Prepared by the BCSH Blood Transfusion Task Force. Br. J. Haematol. 159, 143–153 (2012).
doi: 10.1111/bjh.12017
Day, J., Patel, P., Parkes, J. & Rosenberg, W. Derivation and performance of standardized enhanced liver fibrosis (ELF) test thresholds for the detection and prognosis of liver fibrosis. J. Appl. Lab. Med. 3, 815–826 (2019).
doi: 10.1373/jalm.2018.027359
Friedrich-Rust, M. et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol. 10, 103 (2010).
doi: 10.1186/1471-230X-10-103
Karsdal, M. A. et al. Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev. Technol. 11, 70–92 (2013).
doi: 10.1089/adt.2012.474
Nielsen, M. J. et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am. J. Transl. Res. 5, 303–315 (2013).
pubmed: 23634241
pmcid: 3633973
Veidal, S. S. et al. Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int. 30, 1293–1304 (2010).
doi: 10.1111/j.1478-3231.2010.02309.x
Leeming, D. J. et al. Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis. Scand. J. Gastroenterol. 50, 584–592 (2015).
doi: 10.3109/00365521.2014.996590
Karsdal, M. A. et al. Assessment of liver fibrosis progression and regression by a serological collagen turnover profile. Am. J. Physiol. Gastrointest. Liver Physiol. 316, G25–G31 (2019).
doi: 10.1152/ajpgi.00158.2018
Huo, T. I. et al. Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child–Turcotte–Pugh score. J. Hepatol. 42, 826–832 (2005).
doi: 10.1016/j.jhep.2005.01.019
Barber, K. et al. Elective liver transplant list mortality: development of a United Kingdom end-stage liver disease score. Transplantation 92, 469–476 (2011).
doi: 10.1097/TP.0b013e318225db4d
Loria, A., Escheik, C., Gerber, N. L. & Younossi, Z. M. Quality of life in cirrhosis. Curr. Gastroenterol. Rep. 15, 301 (2013).
doi: 10.1007/s11894-012-0301-5